APIMEDS PHARMACEUTICALS US, INC. Proceeds from (Repayments of) Related Party Debt
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Proceeds from (Repayments of) Related Party Debt of -$76.40 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. proceeds from (repayments of) related party debt for fiscal 2024 was $76.50K, a 750.00% increase from fiscal 2023.
- APIMEDS PHARMACEUTICALS US, INC. proceeds from (repayments of) related party debt for fiscal 2023 was $9.00K.
| Period end | Proceeds from (Repayments of) Related Party Debt | Proceeds from (Repayments of) Related Party Debt 6 month | Proceeds from (Repayments of) Related Party Debt 12 month |
|---|---|---|---|
| 2025-06-30 | -$76.40K 10-Q · filed 2026-08-14 | ||
| 2024-12-31 | $76.50K 10-K · filed 2025-04-15 | ||
| 2023-12-31 | $9.00K 10-K · filed 2025-04-15 | ||
| 2023-03-31 | $9.00K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |